ADMA BIOLOGICS, INC. Accounts Payable and Accrued Liabilities, Fair Value Disclosure
ADMA BIOLOGICS, INC. (ADMA) had Accounts Payable and Accrued Liabilities, Fair Value Disclosure of $290.00 thousand as of 2019-03-31, per its 10-Q filed 2019-05-08.
Discontinued › Notes › Fair Value Disclosures
us-gaap:AccountsPayableAndAccruedLiabilitiesFairValueDisclosure · last filed 2019-05-08
- 2019-03-31: Accounts Payable and Accrued Liabilities, Fair Value Disclosure $290.00K.
- 2018-12-31: Accounts Payable and Accrued Liabilities, Fair Value Disclosure $65.00K.
- 2018-09-30: Accounts Payable and Accrued Liabilities, Fair Value Disclosure $292.50K.
- 2018-06-30: Accounts Payable and Accrued Liabilities, Fair Value Disclosure $62.50K.
| Period end | Accounts Payable and Accrued Liabilities, Fair Value Disclosure | Accounts Payable and Accrued Liabilities, Fair Value Disclosure as first filed |
|---|---|---|
| 2019-03-31 | $290.00K 10-Q · filed 2019-05-08 | |
| 2018-12-31 | $65.00K 10-Q · filed 2019-05-08 | |
| 2018-09-30 | $292.50K 10-Q · filed 2018-11-09 | |
| 2018-06-30 | $62.50K 10-Q · filed 2018-08-10 | |
| 2018-03-31 | $290.00K 10-Q · filed 2018-05-14 | |
| 2017-12-31 | $65.00K 10-K · filed 2019-03-13 | |
| 2017-09-30 | $290.00K 10-Q · filed 2017-11-03 | |
| 2017-06-30 | $60.00K 10-Q · filed 2017-08-11 | |
| 2016-12-31 | $0.00 10-K · filed 2018-03-29 | $60.00K 10-Q · filed 2017-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |